Drug Profile


Alternative Names: AMG-655

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Takeda
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Lymphoma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours

Most Recent Events

  • 13 May 2014 Amgen completes a phase I trial in Lymphoma (combination therapy) in USA (NCT00791011)
  • 01 Oct 2013 Final safety and efficacy data from a phase Ib/II trial in Colorectal cancer released by Amgen
  • 04 Nov 2011 Discontinued - Phase-I for Solid tumours in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top